TMC Ag3
Alternative Names: Ag3; Ag3 AQCs; TMC-Ag3Latest Information Update: 28 Aug 2023
At a glance
- Originator Arjuna Therapeutics
- Developer Arjuna Therapeutics; University of Santiago de Compostela
- Class Antibacterials; Antineoplastics; Radiosensitisers; Small molecules
- Mechanism of Action DNA intercalators; DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Cancer in Spain (PO)
- 26 Jul 2021 Preclinical development in cancer is ongoing in Spain (PO) (Arjuna Therapeutics pipeline, July 2021)
- 26 Jul 2021 Arjuna Therapeutics has patent protection for manufacture and use of multiple TMC molecules (Arjuna Therapeutics pipeline, July 2021)